Publications by authors named "David A Beebe"

Claim this Profile
G
GPAT1 Deficiency in Mice Modulates NASH Progression in a Model-Dependent Manner.
Kathleen R Smith, Wenshan Wang, Melissa R Miller, Magalie Boucher, Jessica E Reynold, David A Beebe

Cell Mol Gastroenterol Hepatol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
Trenton T Ross, Collin Crowley, Kenneth L Kelly, Anthony Rinaldi, David A Beebe

Cell Mol Gastroenterol Hepatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The combination of exercise training and sodium-glucose cotransporter-2 inhibition improves glucose tolerance and exercise capacity in a rodent model of type 2 diabetes.
Melissa A Linden, Trenton T Ross, David A Beebe, Matthew F Gorgoglione, Karyn L Hamilton

Metabolism· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK).
Kim Huard, Kay Ahn, Paul Amor, David A Beebe, Kris A Borzilleri

J Med Chem· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structure.
David A Griffith, Robert L Dow, Kim Huard, David J Edmonds, Scott W Bagley, David A Beebe

J Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of age on noninvasive assessments of vascular function in nonhuman primates: implications for translational drug discovery.
Delvin R Knight, Andrew H Smith, Richard L Schroeder, Chunli Huang, David A Beebe

J Transl Med· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes.
Kim M Andrews, David A Beebe, John W Benbow, David A Boyer, Shawn D Doran

Bioorg Med Chem Lett· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle.
Jeffrey A Pfefferkorn, Jihong Lou, Martha L Minich, Kevin J Filipski, Mingying He, David A Beebe

Bioorg Med Chem Lett· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Failure rates and survival analysis of maxillary expansion appliances: a 24-year retrospective analysis.
David A Beebe, Rocio B Quinonez, Elizabeth A Shick, Se Hee Kim, David B Kennedy

Pediatr Dent· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.
Banavara L Mylari, Sandra J Armento, David A Beebe, Edward L Conn, James B Coutcher

J Med Chem· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of a novel family of triazine-based inhibitors of sorbitol dehydrogenase with oral activity: 1-[4-[3R,5S-dimethyl-4-(4-methyl-[1,3,5]triazin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl]-(R) ethanol.
Banavara L Mylari, Gregory J Withbroe, David A Beebe, Nathaniel S Brackett, Edward L Conn

Bioorg Med Chem· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
X-ray crystallographic and kinetic studies of human sorbitol dehydrogenase.
Thomas A Pauly, Jennifer L Ekstrom, David A Beebe, Boris Chrunyk, David Cunningham

Structure· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one.
Banavara L Mylari, Sandra J Armento, David A Beebe, Edward L Conn, James B Coutcher

J Med Chem· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A sorbitol dehydrogenase inhibitor of exceptional in vivo potency with a long duration of action: 1-(R)-[4-[4-(4,6-dimethyl[1,3,5]triazin-2-yl)- 2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl]ethanol.
Banavara L Mylari, Peter J Oates, William J Zembrowski, David A Beebe, Edward L Conn

J Med Chem· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR and species/stereo-selective metabolism of the sorbitol dehydrogenase inhibitor, CP-470,711.
Margaret Y Chu-Moyer, William E Ballinger, David A Beebe, James B Coutcher, Wesley W Day

Bioorg Med Chem Lett· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally-effective, long-acting sorbitol dehydrogenase inhibitors: synthesis, structure-activity relationships, and in vivo evaluations of novel heterocycle-substituted piperazino-pyrimidines.
Margaret Y Chu-Moyer, William E Ballinger, David A Beebe, Richard Berger, James B Coutcher

J Med Chem· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis